Roundup weedkiller cancer lawsuit: the complete glyphosate litigation guide

Why Roundup litigation remains a massive opportunity

Roundup, the world's most widely used herbicide, has been at the center of one of the largest product liability mass torts in American legal history. Manufactured by Monsanto (now owned by Bayer AG), Roundup contains glyphosate, which IARC classified as a "probable human carcinogen" in 2015. Since then, tens of thousands of plaintiffs have filed lawsuits alleging that Roundup exposure caused their Non-Hodgkin's lymphoma.

Landmark jury verdicts -- including the $289 million Johnson verdict, the $80 million Hardeman verdict, and the $2 billion Pilliod verdict -- established that juries find Monsanto's conduct egregious and its product dangerous. Bayer's subsequent $10.9 billion settlement resolved the majority of pending claims but left thousands of future claims unresolved. More than 18.9 billion pounds of glyphosate have been applied worldwide since 1974, and approximately 300 million pounds are applied annually in the United States alone.

Roundup litigation combines strong scientific evidence, devastating corporate misconduct revelations, and jury verdicts exceeding $2.3 billion -- creating one of the most compelling plaintiff practice areas in mass tort history.

The history of Roundup and glyphosate

Glyphosate was first synthesized in 1950, but its herbicidal properties were not discovered until 1970 by Monsanto chemist John E. Franz. Monsanto patented glyphosate and introduced Roundup as a commercial herbicide in 1974. In the 1990s, Monsanto introduced genetically modified "Roundup Ready" crops, which dramatically increased usage -- global glyphosate use increased approximately 15-fold between 1996 and 2014.

How glyphosate may cause cancer

Research has identified several mechanisms of carcinogenicity: genotoxicity (DNA damage and chromosomal aberrations), oxidative stress, endocrine disruption, immune system suppression, and gut microbiome disruption. Commercial Roundup products also contain surfactants (particularly POEA) that significantly increase toxicity compared to pure glyphosate -- an important distinction since most regulatory assessments evaluated glyphosate in isolation.

IARC classification: glyphosate as a probable carcinogen

In March 2015, IARC classified glyphosate as Group 2A "probable human carcinogen." The panel found "sufficient evidence" of carcinogenicity in experimental animals and "limited evidence" in humans, with "strong mechanistic evidence." This classification has been central to every major Roundup verdict.

IARC vs. EPA: the scientific debate

The EPA has concluded glyphosate is "not likely to be carcinogenic to humans." Key differences explain the divergent conclusions: IARC evaluated only publicly available, peer-reviewed studies while the EPA also considered unpublished industry-sponsored studies. IARC evaluated glyphosate as formulated in commercial products; the EPA focused on glyphosate alone. Juries have consistently found the IARC classification more persuasive, especially after the Monsanto Papers undermined industry-influenced regulatory conclusions.

Non-Hodgkin's lymphoma: the primary cancer linked to Roundup

NHL is a group of cancers originating in the lymphatic system with more than 60 subtypes. A 2019 meta-analysis by Zhang et al. found that high cumulative glyphosate exposure increased NHL risk by 41%. The latency period appears to be approximately 2 to 20+ years, meaning individuals who used Roundup in the 2000s and 2010s may still be developing NHL.

NHL subtypes with strongest evidence

• Diffuse large B-cell lymphoma (DLBCL)
• Follicular lymphoma
• Marginal zone lymphoma
• Mantle cell lymphoma
• Chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)
• Burkitt lymphoma
• T-cell lymphomas
• Waldenstrom's macroglobulinemia

The Monsanto Papers: devastating corporate misconduct

Thousands of internal documents obtained through discovery reveal a systematic campaign to manipulate science, regulatory processes, and public perception. Monsanto employees ghostwrote scientific articles published under outside academics' names. The company launched a coordinated campaign to discredit the IARC classification before it was even published. Communications suggest close relationships between Monsanto and EPA officials, with one reportedly offering to "kill" a separate agency's review of glyphosate.

Landmark Roundup trial verdicts

Dewayne "Lee" Johnson, a school groundskeeper with terminal NHL, was the first plaintiff to take a Roundup case to trial. The jury found Monsanto acted with "malice, oppression, or fraud." Edwin Hardeman, a home gardener who used Roundup for decades, won in a bifurcated federal trial. Alva and Alberta Pilliod, a married couple who both developed NHL, received the largest verdict at $2 billion. These verdicts validated that IARC's classification is admissible and persuasive, and that both occupational and residential exposure support liability.

Bayer's $10.9 billion settlement and remaining claims

In June 2020, Bayer announced a $10.9 billion settlement resolving approximately 100,000 claims. Individual settlement values ranged from approximately $100,000 to $175,000 for most cases. However, thousands of existing cases were not part of the settlement, and future diagnosis cases -- from individuals exposed to Roundup but not yet diagnosed with NHL -- represent an ongoing stream of new claims. In 2021, Bayer removed glyphosate from residential Roundup products, which plaintiffs' attorneys cite as an implicit admission of health risks.

Who qualifies for a Roundup cancer lawsuit

Building a strong Roundup case

Effective case building requires systematic evidence collection: employment records and job descriptions documenting Roundup use, purchase records for home gardeners, application records and spray logs, and witness declarations. Detailed questionnaires documenting frequency, duration, and volume of Roundup use are essential.

Medical causation strategy

Both general causation (can glyphosate cause NHL?) and specific causation (did it cause this plaintiff's NHL?) must be established. Toxicologists and epidemiologists present the IARC classification, meta-analyses, and mechanistic evidence. Oncologists provide differential diagnosis opinions evaluating exposure history, latency period, NHL subtype, and alternative risk factors. The three successful verdicts have validated that this evidence satisfies Daubert.

Common defense arguments

• EPA preemption: Bayer argues state tort claims are preempted because the EPA determined glyphosate is not likely carcinogenic. The Supreme Court declined to hear this argument in Hardeman.
• Regulatory compliance: Compliance with minimum EPA labeling requirements does not shield against tort liability.
• Alternative causation: Defense points to family history, immune disorders, other pesticide exposures, and idiopathic causes.
• Insufficient exposure: For lighter exposure cases, the absence of a known safe threshold and epidemiological evidence at moderate levels counter this argument.

How to acquire Roundup claimants

Building a Roundup caseload requires reaching individuals who used Roundup and have been diagnosed with NHL. Pre-qualified Roundup leads from Mass Tort Agencyprovide a direct source, supplemented by agricultural community outreach through farm bureaus and cooperative extension services, cancer support organization partnerships, workers' compensation cross-referencing for NHL in agricultural workers, and referral networks with agricultural attorneys.

Digital marketing campaigns targeting "Roundup lawsuit," "Roundup cancer lawyer," and "glyphosate lymphoma" reach individuals actively searching for legal help. Agricultural-specific keywords and geographic targeting of farming regions improve efficiency. Social media advertising targets farming communities, gardening enthusiasts, and landscaping professionals.

Cross-referencing related practice areas

Roundup litigation is a natural complement to other product liability and toxic exposure mass torts. Firms active in this area may benefit from diversifying into Camp Lejeune water contamination, AFFF firefighting foam, or Ozempic gastroparesis claims for revenue stability and a broader client base.